Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia

Not Applicable

• Conditions: Chronic Smokers; Hyperlipidemia

• Registration Number: NCT02203227
• Lead Sponsor: Olive Lifesciences Pvt Ltd

Brief Summary

The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 and 60 days of intervention.

Detailed Description

In a randomized, double-blind, placebo control trial, the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) will be investigated in chronic smokers having mild to moderate hyperlipidemia. Sixty subjects will be randomly assigned to receive the dietary supplements and placebo for 60 days. The efficacy of the supplements will be measured by estimating cotinine and malondialdehyde level.

Study Timeline

• Status Verified: 2014-07
• Study First Submitted: 2014-07-28
• Study First Submitted QC: 2014-07-28
• Last Update Submitted: 2014-07-28
• Study First Posted: 2014-07-29
• Last Update Posted: 2014-07-29
• Study Start: 2014-08
• Primary Completion: 2015-02
• Study Completion: 2015-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

• Men > 20 years
• Chronic cigarette/ beedi smoker (2-3 packets/day since last 3 years or more) with mild to moderate hyperlipidemia (LDL ranging 160-189 mg/dL, TC >200 mg/dL and/or HDL-C <40 mg/dL)
• Being mentally competent and able to understand all study requirements and sign the informed consent form.

Exclusion Criteria

• Patients with Chronic obstructive pulmonary disease (COPD)
• Women
• Patients with severe liver, renal, cardiac or brain diseases.
• Unable to complete follow up.
• Subjects on any medication like diuretics.
• Allergic to any medication.
• With a history of alcohol and/or drug abuse.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
change in urine cotinine and serum oxidative stress marker (malondialdehyde) level	Baseline, on day 30 and on day 60

Secondary Outcome Measures

Name	Time	Method
Change in serum lipid profile	Baseline, on day 30 and on day 60	Low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C), high density lipoprotein-cholesterol (HDL-C), total cholesterol (TC)

Trial Locations

Locations (1)

Sreenivasa Clinic Diabetic Research Center; 🇮🇳 Bangalore, Karnataka, India